SK284142B6 - Farmaceutická kompozícia na reguláciu koncentrácie lipidov, stabilizáciu aterosklerotických lézií a na prevenciu pretrhnutia aterosklerotického plaku - Google Patents
Farmaceutická kompozícia na reguláciu koncentrácie lipidov, stabilizáciu aterosklerotických lézií a na prevenciu pretrhnutia aterosklerotického plaku Download PDFInfo
- Publication number
- SK284142B6 SK284142B6 SK557-98A SK55798A SK284142B6 SK 284142 B6 SK284142 B6 SK 284142B6 SK 55798 A SK55798 A SK 55798A SK 284142 B6 SK284142 B6 SK 284142B6
- Authority
- SK
- Slovakia
- Prior art keywords
- phenyl
- methylethyl
- atorvastatin
- acetyl
- tris
- Prior art date
Links
- 150000002632 lipids Chemical class 0.000 title claims abstract description 7
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 9
- 238000000034 method Methods 0.000 title description 4
- 230000001105 regulatory effect Effects 0.000 title description 3
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims abstract description 22
- 229960005370 atorvastatin Drugs 0.000 claims abstract description 22
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims abstract description 21
- -1 [[2,4,6-tris(1- methylethyl)phenyl]acetyl]- Chemical class 0.000 claims abstract description 13
- 230000003902 lesion Effects 0.000 claims description 19
- 230000003143 atherosclerotic effect Effects 0.000 claims description 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 6
- 208000037260 Atherosclerotic Plaque Diseases 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000000087 stabilizing effect Effects 0.000 claims description 2
- 229940123324 Acyltransferase inhibitor Drugs 0.000 claims 2
- 239000002404 acyltransferase inhibitor Substances 0.000 claims 2
- 239000007983 Tris buffer Substances 0.000 claims 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-M sulfamate Chemical compound NS([O-])(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-M 0.000 claims 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 31
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 abstract description 10
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 abstract description 10
- 108090001030 Lipoproteins Proteins 0.000 abstract description 8
- 102000004895 Lipoproteins Human genes 0.000 abstract description 8
- 235000012000 cholesterol Nutrition 0.000 abstract description 8
- 230000002792 vascular Effects 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 7
- 238000008214 LDL Cholesterol Methods 0.000 abstract description 6
- 230000001419 dependent effect Effects 0.000 abstract description 6
- 230000000302 ischemic effect Effects 0.000 abstract description 6
- 230000009467 reduction Effects 0.000 abstract description 6
- 239000003112 inhibitor Substances 0.000 abstract description 5
- 208000011580 syndromic disease Diseases 0.000 abstract description 5
- 238000011282 treatment Methods 0.000 abstract description 5
- 230000000923 atherogenic effect Effects 0.000 abstract description 4
- 239000003795 chemical substances by application Substances 0.000 abstract description 4
- LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 description 11
- PTQXTEKSNBVPQJ-UHFFFAOYSA-N Avasimibe Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1CC(=O)NS(=O)(=O)OC1=C(C(C)C)C=CC=C1C(C)C PTQXTEKSNBVPQJ-UHFFFAOYSA-N 0.000 description 9
- 125000004432 carbon atom Chemical group C* 0.000 description 9
- 108010028554 LDL Cholesterol Proteins 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 7
- 125000000217 alkyl group Chemical group 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- 200000000007 Arterial disease Diseases 0.000 description 6
- 201000001320 Atherosclerosis Diseases 0.000 description 6
- 108010069201 VLDL Cholesterol Proteins 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000002775 capsule Substances 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 210000001105 femoral artery Anatomy 0.000 description 5
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 108010023302 HDL Cholesterol Proteins 0.000 description 4
- 208000035150 Hypercholesterolemia Diseases 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 230000003511 endothelial effect Effects 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 210000000115 thoracic cavity Anatomy 0.000 description 4
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 3
- 108010010234 HDL Lipoproteins Proteins 0.000 description 3
- 102000015779 HDL Lipoproteins Human genes 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 235000015263 low fat diet Nutrition 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 210000000689 upper leg Anatomy 0.000 description 3
- 102000018616 Apolipoproteins B Human genes 0.000 description 2
- 108010027006 Apolipoproteins B Proteins 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 102100030817 Liver carboxylesterase 1 Human genes 0.000 description 2
- 101710181187 Liver carboxylesterase 1 Proteins 0.000 description 2
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 2
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 230000000879 anti-atherosclerotic effect Effects 0.000 description 2
- 210000002376 aorta thoracic Anatomy 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000011284 combination treatment Methods 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 210000003989 endothelium vascular Anatomy 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 229960003765 fluvastatin Drugs 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- NPQWVLZCVMVSEX-UHFFFAOYSA-N n-[2,6-di(propan-2-yl)phenyl]-2-(2-dodecyltetrazol-5-yl)-2-phenylacetamide Chemical compound CCCCCCCCCCCCN1N=NC(C(C(=O)NC=2C(=CC=CC=2C(C)C)C(C)C)C=2C=CC=CC=2)=N1 NPQWVLZCVMVSEX-UHFFFAOYSA-N 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- SWYZGLWCQFMQJW-UHFFFAOYSA-N phenoxy hypofluorite Chemical compound FOOC1=CC=CC=C1 SWYZGLWCQFMQJW-UHFFFAOYSA-N 0.000 description 2
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 2
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- KJTLQQUUPVSXIM-ZCFIWIBFSA-M (R)-mevalonate Chemical compound OCC[C@](O)(C)CC([O-])=O KJTLQQUUPVSXIM-ZCFIWIBFSA-M 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- HSHOXDTWEUKPND-UHFFFAOYSA-N 5-methoxy-5-oxopentaneperoxoic acid Chemical compound COC(=O)CCCC(=O)OO HSHOXDTWEUKPND-UHFFFAOYSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010065558 Aortic arteriosclerosis Diseases 0.000 description 1
- 101710095342 Apolipoprotein B Proteins 0.000 description 1
- 102100040202 Apolipoprotein B-100 Human genes 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- KJTLQQUUPVSXIM-UHFFFAOYSA-N DL-mevalonic acid Natural products OCCC(O)(C)CC(O)=O KJTLQQUUPVSXIM-UHFFFAOYSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 description 1
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 1
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000181 anti-adherent effect Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 239000003529 anticholesteremic agent Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 201000001962 aortic atherosclerosis Diseases 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 230000007213 cerebrovascular event Effects 0.000 description 1
- GPUADMRJQVPIAS-QCVDVZFFSA-M cerivastatin sodium Chemical compound [Na+].COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 GPUADMRJQVPIAS-QCVDVZFFSA-M 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229960003627 gemfibrozil Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940095570 lescol Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- QWDJLDTYWNBUKE-UHFFFAOYSA-L magnesium bicarbonate Chemical compound [Mg+2].OC([O-])=O.OC([O-])=O QWDJLDTYWNBUKE-UHFFFAOYSA-L 0.000 description 1
- 235000014824 magnesium bicarbonate Nutrition 0.000 description 1
- 239000002370 magnesium bicarbonate Substances 0.000 description 1
- 229910000022 magnesium bicarbonate Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229940099246 mevacor Drugs 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000007491 morphometric analysis Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 229940089484 pravachol Drugs 0.000 description 1
- 229960002965 pravastatin Drugs 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000011555 rabbit model Methods 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 206010038464 renal hypertension Diseases 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- PCLPZFJBZOVJSU-UHFFFAOYSA-N sulfamoyl 2-[2,4,6-tri(propan-2-yl)phenyl]acetate Chemical compound CC(C)C1=CC(C(C)C)=C(CC(=O)OS(N)(=O)=O)C(C(C)C)=C1 PCLPZFJBZOVJSU-UHFFFAOYSA-N 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 208000032598 susceptibility microvascular complications of diabetes Diseases 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 230000004218 vascular function Effects 0.000 description 1
- 230000006442 vascular tone Effects 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 239000011345 viscous material Substances 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 229940072168 zocor Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/36—Antigestagens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US615595P | 1995-11-02 | 1995-11-02 | |
| PCT/US1996/015854 WO1997016184A1 (en) | 1995-11-02 | 1996-10-02 | Method and pharmaceutical composition for regulating lipid concentration |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SK55798A3 SK55798A3 (en) | 1999-06-11 |
| SK284142B6 true SK284142B6 (sk) | 2004-10-05 |
Family
ID=21719566
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK557-98A SK284142B6 (sk) | 1995-11-02 | 1996-10-02 | Farmaceutická kompozícia na reguláciu koncentrácie lipidov, stabilizáciu aterosklerotických lézií a na prevenciu pretrhnutia aterosklerotického plaku |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US6124309A (enExample) |
| EP (1) | EP0858336B1 (enExample) |
| JP (1) | JPH11515025A (enExample) |
| KR (2) | KR100449604B1 (enExample) |
| CN (2) | CN1217656C (enExample) |
| AR (1) | AR004527A1 (enExample) |
| AT (1) | ATE348607T1 (enExample) |
| AU (1) | AU720853B2 (enExample) |
| BG (1) | BG64018B1 (enExample) |
| BR (1) | BR9611410A (enExample) |
| CZ (1) | CZ127198A3 (enExample) |
| DE (1) | DE69636783T2 (enExample) |
| EA (1) | EA000514B1 (enExample) |
| ES (1) | ES2279526T3 (enExample) |
| GE (1) | GEP20001898B (enExample) |
| HU (1) | HUP9901865A3 (enExample) |
| IL (1) | IL123902A (enExample) |
| IS (1) | IS4720A (enExample) |
| NO (1) | NO981961L (enExample) |
| NZ (2) | NZ319906A (enExample) |
| PL (1) | PL186714B1 (enExample) |
| RO (1) | RO120816B1 (enExample) |
| SK (1) | SK284142B6 (enExample) |
| UA (1) | UA46069C2 (enExample) |
| WO (1) | WO1997016184A1 (enExample) |
| ZA (1) | ZA969187B (enExample) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6268392B1 (en) * | 1994-09-13 | 2001-07-31 | G. D. Searle & Co. | Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors |
| SK284142B6 (sk) * | 1995-11-02 | 2004-10-05 | Warner-Lambert Company | Farmaceutická kompozícia na reguláciu koncentrácie lipidov, stabilizáciu aterosklerotických lézií a na prevenciu pretrhnutia aterosklerotického plaku |
| GT199800126A (es) * | 1997-08-29 | 2000-01-29 | Terapia de combinacion. | |
| GT199800127A (es) * | 1997-08-29 | 2000-02-01 | Combinaciones terapeuticas. | |
| SI1009400T1 (en) * | 1997-08-29 | 2005-04-30 | Pfizer Inc. | Combination therapy comprising atorvastatin and an antihypertensive agent |
| AU1591699A (en) * | 1998-03-17 | 1999-10-11 | Warner-Lambert Company | Statin-matrix metalloproteinase inhibitor combinations |
| US6221897B1 (en) * | 1998-06-10 | 2001-04-24 | Aventis Pharma Deutschland Gmbh | Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use |
| SK4122001A3 (en) * | 1998-09-30 | 2002-06-04 | Warner Lambert Co | Method for preventing or delaying catheter-based revascularization |
| CO5140104A1 (es) * | 1999-02-16 | 2002-03-22 | Novartis Ag | Derivados de mevinolina y preparacion farmaceuticas que los contienen |
| US20010006656A1 (en) * | 1999-02-17 | 2001-07-05 | University Of Washington | Methods and compositions for inhibiting inflammation associated with pulmonary disease |
| WO2001022962A1 (en) * | 1999-09-30 | 2001-04-05 | Merck & Co., Inc. | Anti-hypercholesterolemic drug combination |
| EP1092432A1 (fr) | 1999-10-15 | 2001-04-18 | Societe De Conseils De Recherches Et D'applications Scientifiques S.A. (S.C.R.A.S.) | Composes anti-ischemiques |
| HUP0203160A3 (en) * | 1999-11-05 | 2006-02-28 | Warner Lambert Co | Prevention of plaque rupture by acat inhibitors |
| HUP0301728A3 (en) * | 2000-09-01 | 2004-05-28 | Sankyo Co | Hmg-coa reductase inhibiting pharmaceutical compositions and their use |
| US6703422B2 (en) | 2000-10-11 | 2004-03-09 | Esperion Therapeutics, Inc. | Sulfide and disulfide compounds and compositions for cholesterol management and related uses |
| US6713507B2 (en) | 2000-10-11 | 2004-03-30 | Esperion Therapeutics, Inc. | Ether compounds and compositions for cholesterol management and related uses |
| CN1479721A (zh) | 2000-10-11 | 2004-03-03 | ͨ��ҽ�ƹ�˾ | 用于胆固醇治疗和相关应用的亚砜和双亚砜化合物和组合物 |
| US7304093B2 (en) * | 2000-10-11 | 2007-12-04 | Esperion Therapeutics, Inc. | Ketone compounds and compositions for cholesterol management and related uses |
| US20040122091A1 (en) * | 2000-10-11 | 2004-06-24 | Esperion Therapeutics, Inc. | Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses |
| AU2002213136B2 (en) | 2000-10-11 | 2007-01-04 | Esperion Therapeutics, Inc. | Ketone compounds and compositions for cholesterol management and related uses |
| CA2369967A1 (en) * | 2001-02-12 | 2002-08-12 | Joseph Anthony Cornicelli | Methods of treating nuclear factor-kappa b mediated diseases and disorders |
| PE20030324A1 (es) * | 2001-07-31 | 2003-04-03 | Warner Lambert Co | Composiciones farmaceuticas de amlodipina y atorvastatina |
| US20040204502A1 (en) * | 2001-10-11 | 2004-10-14 | Dasseux Jean-Louis Henri | Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses |
| US20040192771A1 (en) * | 2001-10-11 | 2004-09-30 | Dasseux Jean-Louis Henri | Ether compounds and compositions for cholesterol management and related uses |
| US20050020694A1 (en) * | 2001-10-11 | 2005-01-27 | Dasseux Jean-Louis Henri | Sulfide and disulfide compounds and compositions for cholesterol management and related uses |
| CA2478184A1 (en) * | 2002-03-12 | 2003-09-25 | Merck & Co., Inc. | Drug combination therapy |
| WO2003087108A2 (en) * | 2002-04-10 | 2003-10-23 | Esperion Therapeutics, Inc. | Mimics of acyl coenzyme-a, compositions thereof, and methods of cholesterol management and related uses |
| JP4187141B2 (ja) * | 2002-04-12 | 2008-11-26 | 興和株式会社 | 新規なトロンボモジュリン発現促進剤 |
| WO2004067489A2 (en) * | 2003-01-23 | 2004-08-12 | Esperion Therapeutics, Inc. | Hydroxyl compounds and compositions for cholesterol management and related uses |
| CN100438872C (zh) | 2003-08-29 | 2008-12-03 | 兴和株式会社 | 2-[4-[2-(苯并咪唑-2-基-硫代)乙基]哌嗪-1-基]-n-[2,4-二(甲基硫代)-6-甲基-3-吡啶基]乙酰胺的制药用途 |
| CA2546079A1 (en) * | 2003-11-17 | 2005-05-26 | Toyo Shinyaku Co., Ltd. | Lipometabolism improver containing pine bark extract |
| EP1701931B1 (en) | 2003-12-24 | 2018-10-10 | Esperion Therapeutics, Inc. | Ketone compounds and compositions for cholesterol management and related uses |
| CA2563693C (en) * | 2004-04-19 | 2010-07-06 | Loma Linda University | Composition and method of decreasing renal ischemic damage |
| TW200605890A (en) * | 2004-07-28 | 2006-02-16 | Sankyo Co | Pharmaceutical compositions for inhibiting arteriosclerosis |
| MX2007005129A (es) * | 2004-10-27 | 2007-09-11 | Daiichi Sankyo Co Ltd | Compuesto de benceno que tiene 2 o mas sustituyentes. |
| TW200619204A (en) * | 2004-12-10 | 2006-06-16 | Kowa Co | Method for reduction, stabilization and prevention of rupture of lipid rich plaque |
| EP1948599A1 (en) * | 2005-11-08 | 2008-07-30 | Ranbaxy Laboratories Limited | Process for (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt |
| RU2308947C1 (ru) * | 2006-02-26 | 2007-10-27 | Новосибирский институт органической химии им. Н.Н. Ворожцова СО РАН (НИОХ СО РАН) | Лекарственное средство с гиполипидемическим эффектом "симваглизин" |
| PL2018153T3 (pl) | 2006-04-26 | 2012-09-28 | Rosemont Pharmaceuticals Ltd | Ciekłe kompozycje doustne |
| US20130254787A1 (en) | 2006-05-02 | 2013-09-26 | Invidi Technologies Corporation | Method and apparatus to perform real-time audience estimation and commercial selection suitable for targeted advertising |
| US20070269503A1 (en) * | 2006-05-16 | 2007-11-22 | James Walter Burgess | Combinations of HMG CoA reductase inhibitors and negatively charged phospholipids and uses thereof |
| US8314080B2 (en) | 2010-04-06 | 2012-11-20 | Kuwait University | Method of treating type I diabetes |
| CN103288702B (zh) * | 2010-12-03 | 2015-09-16 | 上海科州药物研发有限公司 | 一种阿托伐他汀氨基酸盐的制备方法 |
| US8586527B2 (en) * | 2011-10-20 | 2013-11-19 | Jaipal Singh | Cerivastatin to treat pulmonary disorders |
| MX363161B (es) | 2011-10-28 | 2019-03-13 | Lumena Pharmaceuticals Inc | Inhibidores de la recirculación de ácidos biliares para el tratamiento de hipercolemia y enfermedad hepática colestásica. |
| WO2013063512A1 (en) | 2011-10-28 | 2013-05-02 | Lumena Pharmaceuticals, Inc | Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases |
| CN103304496A (zh) * | 2012-03-08 | 2013-09-18 | 南京工业大学 | 一种合成申嗪霉素方法 |
| WO2013171100A1 (en) | 2012-05-16 | 2013-11-21 | Joachim Hans | Polyhydroxylated pentacyclic triterpene acids as hmg-coa reductase inhibitors |
| MA42616A (fr) | 2015-03-13 | 2021-05-19 | Esperion Therapeutics Inc | Combinaisons et formulations de doses fixes comprenant etc1002 et ézétimibe, et procédés de traitement ou de réduction du risque de maladie cardio-vasculaire |
| MA41793A (fr) | 2015-03-16 | 2018-01-23 | Esperion Therapeutics Inc | Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire |
| CA3144372A1 (en) | 2019-06-21 | 2020-12-24 | Esperion Therapeutics, Inc. | Salt forms of bempedoic acid and methods for using the same |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4739073A (en) * | 1983-11-04 | 1988-04-19 | Sandoz Pharmaceuticals Corp. | Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof |
| CA2003478A1 (en) * | 1988-12-12 | 1990-06-12 | Leonard G. Dennick | Combination of an hmg coa reductase inhibitor and other type of serum cholesterol reducing agent and method for lowering serum cholesterol using such combination |
| FI94339C (fi) * | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
| CA2048395A1 (en) * | 1990-08-23 | 1992-02-24 | Henry Y. Pan | Method for preventing onset of or treating type iii hyperlipoproteinemia employing pravastatin |
| DE69222532T2 (de) | 1991-07-23 | 1998-02-26 | Schering Corp | Substituierte beta-lactam-verbindungen als hypocholesterolemische mittel und verfahren zu deren herstellung |
| AU5538794A (en) * | 1992-10-26 | 1994-05-24 | Merck & Co., Inc. | Biologically active compounds and process therefor |
| LT3300B (en) | 1992-12-23 | 1995-06-26 | Schering Corp | Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor |
| IL109431A (en) * | 1993-05-14 | 2001-01-11 | Warner Lambert Co | Pharmaceutical compositions containing n-acyl sulfamic acid esters (or thioesters), n-acyl sulfonamides, and n-sulfonyl carbamic acid esters (or thioesters), for regulating plasma cholesterol concentration, and certain such novel compounds |
| US5491172A (en) * | 1993-05-14 | 1996-02-13 | Warner-Lambert Company | N-acyl sulfamic acid esters (or thioesters), N-acyl sulfonamides, and N-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents |
| AU1095695A (en) * | 1993-11-09 | 1995-05-29 | Brigham And Women's Hospital | Hmg-coa reductase inhibitors in the normalization of vascular endothelial dysfunction |
| SK284142B6 (sk) * | 1995-11-02 | 2004-10-05 | Warner-Lambert Company | Farmaceutická kompozícia na reguláciu koncentrácie lipidov, stabilizáciu aterosklerotických lézií a na prevenciu pretrhnutia aterosklerotického plaku |
-
1996
- 1996-10-02 SK SK557-98A patent/SK284142B6/sk unknown
- 1996-10-02 KR KR10-1998-0703240A patent/KR100449604B1/ko not_active Expired - Fee Related
- 1996-10-02 UA UA98052811A patent/UA46069C2/uk unknown
- 1996-10-02 EP EP96934020A patent/EP0858336B1/en not_active Revoked
- 1996-10-02 RO RO98-00919A patent/RO120816B1/ro unknown
- 1996-10-02 EA EA199800420A patent/EA000514B1/ru not_active IP Right Cessation
- 1996-10-02 AT AT96934020T patent/ATE348607T1/de not_active IP Right Cessation
- 1996-10-02 BR BR9611410A patent/BR9611410A/pt not_active Application Discontinuation
- 1996-10-02 WO PCT/US1996/015854 patent/WO1997016184A1/en not_active Ceased
- 1996-10-02 CN CN961980109A patent/CN1217656C/zh not_active Expired - Fee Related
- 1996-10-02 US US09/051,368 patent/US6124309A/en not_active Expired - Fee Related
- 1996-10-02 AU AU72539/96A patent/AU720853B2/en not_active Ceased
- 1996-10-02 IL IL12390296A patent/IL123902A/xx not_active IP Right Cessation
- 1996-10-02 NZ NZ319906A patent/NZ319906A/en unknown
- 1996-10-02 PL PL96326365A patent/PL186714B1/pl not_active IP Right Cessation
- 1996-10-02 KR KR10-2004-7003107A patent/KR20040029459A/ko not_active Ceased
- 1996-10-02 JP JP9517342A patent/JPH11515025A/ja not_active Ceased
- 1996-10-02 CN CNA2005100517235A patent/CN1679953A/zh active Pending
- 1996-10-02 CZ CZ981271A patent/CZ127198A3/cs unknown
- 1996-10-02 DE DE69636783T patent/DE69636783T2/de not_active Expired - Fee Related
- 1996-10-02 NZ NZ512484A patent/NZ512484A/xx unknown
- 1996-10-02 ES ES96934020T patent/ES2279526T3/es not_active Expired - Lifetime
- 1996-10-02 GE GEAP19964269A patent/GEP20001898B/en unknown
- 1996-10-02 HU HU9901865A patent/HUP9901865A3/hu unknown
- 1996-10-31 ZA ZA969187A patent/ZA969187B/xx unknown
- 1996-11-01 AR ARP960105005A patent/AR004527A1/es unknown
-
1998
- 1998-04-17 IS IS4720A patent/IS4720A/is unknown
- 1998-04-29 BG BG102417A patent/BG64018B1/bg unknown
- 1998-04-30 NO NO981961A patent/NO981961L/no unknown
-
1999
- 1999-07-01 US US09/345,944 patent/US6093719A/en not_active Expired - Fee Related
- 1999-07-01 US US09/346,503 patent/US6143755A/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SK284142B6 (sk) | Farmaceutická kompozícia na reguláciu koncentrácie lipidov, stabilizáciu aterosklerotických lézií a na prevenciu pretrhnutia aterosklerotického plaku | |
| US5190970A (en) | Method for preventing onset of or treating Type II diabetes employing a cholesterol lowering drug alone or in combination with an ace inhibitor | |
| US5593971A (en) | Method for preventing onset of hypertension employing a cholesterol lowering drug | |
| US5130333A (en) | Method for treating type II diabetes employing a cholesterol lowering drug | |
| USH1286H (en) | Method for treating peripheral atherosclerotic disease employing a cholesterol lowering drug, an ace inhibitor, or a combination thereof | |
| KR100200467B1 (ko) | 콜레스테롤 저하제 및 ace 억제제로 이루어진 아테롬성 동맥경화증의 예방, 안정화 또는 경감용 조성물 | |
| EP0455042A1 (en) | Combination of pravastatin and a fibric acid derivative, and method for treating dyslipidemia using such combination | |
| EP0475148A1 (en) | Pravastatin alone or in combination with a fibric acid derivative for preventing onset of or treating type III hyperlipoproteinemia | |
| US6245800B1 (en) | Method of preventing or treating statin-induced toxic effects using L-carnitine or an alkanoyl L-carnitine | |
| KR100725263B1 (ko) | ＨＭＧ-ＣｏＡ 리덕타제 억제제 및 카르니틴을 포함하는 항지질혈성 복합제 | |
| CA2233558C (en) | Method and pharmaceutical composition for regulating lipid concentration | |
| US6630502B2 (en) | Method for preventing, stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor | |
| CA2413906A1 (en) | Carboxyalkylether-acat inhibitor combinations |